Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead drug candidate APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. Aprea has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine. Additional Phase 1/2 trials of APR-246 in MDS and AML, in combination with approved anti-cancer therapies, are also underway and in planning. Aprea is also developing next generation p53 reactivators.